DTMT Network

The global pharmaceutical giant Bayer AG said that it will present the findings of its key scientific researches in oncology at the upcoming European Society for Medical Oncology’s ESMO Congress 2022, scheduled to be held from September 9-13, 2022, which will highlight the company's commitment to advancing unmet needs in prostate cancer, providing expertise in precision medicine, and working on immunotherapy combinations.

In a statement released recently, Bayer informed that it will present the trial data from three studies, the first of which is the data from  the Phase III ARASENS trial for its  darolutamide, marketed under the brand, Nubeqa for those living with metastatic hormone-sensitive prostate cancer (mHSPC)

The drug has been approved in more than 70 countries, and has been approved by the U.S. Food and Drug Administration in combination with docetaxel in mHSPC and submitted applications for darolutamide in combination with docetaxel in mHSPC to the European Medicine Agency, among others, the company said.

Additionally, Bayer will present data from the trial with radium-223 dichloride, which includes safety and effectiveness outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-prostate-specific membrane antigen after radium-223 dichloride.

This data not only focuses on the treatment sequence of radium-223 dichloride followed by 177Lu-PSMA but also includes data on the feasibility of adding docetaxel in the treatment pathway, the statement added.

On the precision oncology front, the company said that it will present data from larotrectinib clinical trials in paediatric and adult patients with NTRK gene fusion-positive solid tumours, a genetic mutation that occurs when a piece of the chromosome containing a gene called NTRK breaks off and joins with a gene on another chromosome leading to uncontrolled proliferation of cancer cells.

The presentation will include an expanded intra-patient comparison dataset in TRK fusion cancer and efficacy and safety data in a pooled analysis of patients with TRK fusion cancer with an extended follow-up, Bayer said.